Press release
Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
Protease inhibitor is a key component of platform technology that protects therapeutic proteins in the digestive system NEW YORK, Jan. 28, 2020 /PRNewswire/
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"Protease inhibitor is a key component of platform technology that protects therapeutic proteins in the digestive system\n\n\nNEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent to grant the Company a patent for its invention titled \"Methods and Compositions for Oral Administration of Proteins,\" addressing oral compositions comprising protease inhibitors, which are a key component of the platform technology that protects therapeutic proteins in the digestive system. \n\n \n \n\n \nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 and Type 1 diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.\nFor more information, please visit www.oramed.com.\nForward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results t...